Iancu Gabriela Mariana, Ocneanu Anca, Rotaru Maria
Dermatology Department, Faculty of Medicine, University Lucian Blaga of Sibiu, 550169 Sibiu, Romania.
Clinic of Dermatology, County Emergency Hospital of Sibiu, 550245 Sibiu, Romania.
Exp Ther Med. 2020 Dec;20(6):191. doi: 10.3892/etm.2020.9321. Epub 2020 Oct 14.
The chronic use of hydroxyurea (HU) in some oncologic and non-oncologic diseases (psoriasis, sickle cell anemia) can be accompanied by side effects, both systemic and mucocutaneous. The most severe adverse events known in HU therapy are leg ulcers and cutaneous carcinomas. At skin level may also appear: xerosis, persistent pruritus, skin color changes (erythema, hyperpigmentation), cutaneous atrophy. Likewise, oral ulcerations and stomatitis may occur at mucosal level. Hair damage can be expressed through alopecia and nail damage through melanonychia and oncycholysis. First case, a 63-year-old woman with severe psoriasis vulgaris and chronic granulocytic leukemia, with 5 years of HU therapy, was admitted to hospital for submammary and palmoplantar ulcers, superinfected with methicillin-resistant and . Clinical exam showed that the patient had also cutaneous atrophy, marked palmoplantar xerosis and melanonychia. The second case, a 72-year-old woman with primary thrombocytemia, treated with HU for 3 years, presented with necrotic leg ulcers that were superinfected with , and . The patient associates cellulitis, microbial eczema and xeroderma. In both cases, after HU discontinuation, systemic antibiotics, topical epithelizing agents and emollients, the ulcers had a slow favorable evolution. In our cases, the ulcers appeared after 5, respectively 3 years of HU therapy. It is stressed that in the first case, which had associated psoriasis, after 1 year of 1 g of HU/day, the psoriatic lesions completely disappeared. The severe progression of the ulcers was also favored by the superinfection of the ulcers with 2, respectively, 3 identified germs for which appropriate systemic antibiotics was required.
在某些肿瘤性和非肿瘤性疾病(如银屑病、镰状细胞贫血)中长期使用羟基脲(HU)可能会伴随全身和皮肤黏膜方面的副作用。HU治疗中已知的最严重不良事件是腿部溃疡和皮肤癌。在皮肤层面还可能出现:皮肤干燥、持续性瘙痒、皮肤颜色改变(红斑、色素沉着)、皮肤萎缩。同样,在黏膜层面可能会发生口腔溃疡和口腔炎。毛发损伤可表现为脱发,指甲损伤表现为甲下黑素沉着和甲脱离。第一个病例是一名63岁患有重度寻常型银屑病和慢性粒细胞白血病的女性,接受HU治疗5年,因乳房下和掌跖溃疡入院,溃疡合并耐甲氧西林的[具体病菌1]和[具体病菌2]感染。临床检查显示该患者还存在皮肤萎缩、明显的掌跖皮肤干燥和甲下黑素沉着。第二个病例是一名72岁患有原发性血小板增多症的女性,接受HU治疗3年,出现坏死性腿部溃疡,合并[具体病菌3]、[具体病菌4]和[具体病菌5]感染。该患者伴有蜂窝织炎、微生物性湿疹和皮肤干燥症。在这两个病例中,停用HU、使用全身抗生素、局部上皮修复剂和润肤剂后,溃疡缓慢好转。在我们的病例中,溃疡分别在HU治疗5年和3年后出现。需要强调的是,在第一个合并银屑病的病例中,每日服用1克HU 1年后,银屑病皮损完全消失。溃疡的严重进展还因溃疡分别合并2种和3种已鉴定出的病菌感染而加重,为此需要使用合适的全身抗生素。